Gilead and Teva Reach Settlement Agreement in Viread® Patent Litigation

Business Wirevia The Motley Fool
Updated

Gilead and Teva Reach Settlement Agreement in Viread®Patent Litigation

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NAS: GILD) today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread® (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

"We believe strongly in the validity of our intellectual property," said John Milligan, PhD, Gilead's President and Chief Operating Officer. "This settlement, however, removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation."


The trial in this litigation, which was scheduled to begin on Wednesday, February 20 in the District Court for the Southern District of New York, has been adjourned pending completion of activities necessary to finalize the settlement.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

For more information on Gilead Sciences, please visit the company's website atwww.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.



Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)

KEYWORDS: United States Europe North America California

INDUSTRY KEYWORDS:

The article Gilead and Teva Reach Settlement Agreement in Viread® Patent Litigation originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement